The evidence-based starting dose of 0.25mg activates MC1R-mediated melanogenesis without oversaturating MC4R, allowing gradual receptor adaptation during titration
However, only pimitespib, an oral inhibitor developed by Taiho Pharmaceutical, was approved in Japan in 2022 for gastrointestinal stromal tumors, and it is currently the focus of a phase I study for the treatment of solid tumors in the EU and USA [7, 8]
Carnitine does not have an established tolerable upper intake level [1]
Infusion therapy may support recovery after microneedling, laser treatments, or intense travel and stress
359 Furthermore, the ongoing Phase 3 persevERA (NCT04546009) clinical trial investigates the efficacy of combining giredestrant and palbociclib as a first-line treatment for metastatic breast cancer